Silence Therapeutics prices upsized $175 million public offering

Silence Therapeutics, a clinical-stage biotechnology company specializing in short interfering RNA (siRNA) therapies, has priced an upsized underwritten public offering of 12,962,963 American Depositary Shares (ADSs). The offering is priced at $13.50 per ADS, with gross proceeds expected to reach approximately $175 million before discounts and expenses. Underwriters have been granted a 30-day option to purchase up to an additional 1,944,444 ADSs.

Following the announcement, the company's share price saw a significant increase, opening at $16.70 after a previous close of $11.95. While recent quarterly earnings reported a loss of $0.27 per share, analysts maintain varying outlooks, including an overweight rating from Cantor Fitzgerald and a buy rating from HC Wainwright with a $75.00 price objective. The offering is expected to close around August 13, 2026.